Moving to Tirzepatide After Semaglutide: What Actually Happens

Step 1, understanding why someone considers the switch

Most people who ask about tirzepatide after semaglutide fall into one of three groups: those who lost weight on semaglutide but have plateaued, those who found the GI side effects on semaglutide difficult to manage, and those who simply want to try the medicine that produced stronger average results in clinical trials. All three are legitimate clinical reasons to explore a switch, and none of them is unusual. Our prescribers hear this question most weeks.

It helps to understand the mechanical difference first. Semaglutide (Wegovy) acts on a single pathway, the GLP-1 receptor, to reduce appetite and slow gastric emptying. Tirzepatide (Mounjaro) acts on two: GLP-1 and GIP. That dual action is the reason its trial results differ. In SURMOUNT-1, participants on 15mg tirzepatide lost around 20–21% of body weight on average over 72 weeks, compared with roughly 15% in the STEP 1 trial of semaglutide 2.4mg at 68 weeks, and in the direct head-to-head SURMOUNT-5 trial, published in the New England Journal of Medicine, tirzepatide produced greater average weight loss than semaglutide 2.4mg over 72 weeks. These are population averages from clinical trials; individual results vary.

If you want a broader side-by-side read before going further, the Wegovy vs Mounjaro comparison covers the full picture of both medicines.

Step 2, what changes when you switch medicines

Moving from semaglutide to tirzepatide is not a continuation of the same treatment at a higher dose. They are different molecules with different receptor profiles, which is why the prescriber needs to assess your history rather than simply carry it over.

In practice, patients switching from semaglutide typically restart at tirzepatide's 2.5mg starting dose. The first pen's job is to let your system adjust to the new molecule, particularly its GIP action, before titration begins. That adjustment period matters, people who have tolerated semaglutide well sometimes assume they can skip straight to a higher tirzepatide dose, but the two medicines are not interchangeable on a like-for-like basis.

Storage routine shifts too: like semaglutide, tirzepatide pens are refrigerated, but the specific room-temperature window and handling details differ between the two. Keep the current pen's Patient Information Leaflet to hand rather than carrying over habits from your previous treatment. The electronic Medicines Compendium (eMC) holds the full Summary of Product Characteristics for both medicines if you want to compare the storage sections directly.

A question we see regularly is whether there is a washout period. The current clinical consensus is that no washout is required between semaglutide and tirzepatide, but the prescriber confirms that based on your individual circumstances. Questions about timing, dose-matching and your specific medical history are exactly what the consultation is for, and if you are still weighing up whether semaglutide or tirzepatide is the right choice for you, that page sets out the key considerations before you decide. You can also read more about how the two medicines relate in detail at is tirzepatide the same as semaglutide.

Step 3, comparing the two medicines at a glance

The table below pulls together the key factual differences. Numbers from clinical trials are cited; the NICE recommendations cited are from TA1026 (tirzepatide) and TA875 (semaglutide).

Neither medicine is universally 'better'. The SURMOUNT-5 result gives tirzepatide an average edge in weight reduction, but side-effect profiles, medical history, oral vs injection preference, and individual response all shape the clinical decision. If you want a fuller breakdown of the evidence on each side, our page on which of semaglutide or tirzepatide performs better goes into the trial data in more detail. For a deeper look at the effectiveness comparison, this comparison of semaglutide and tirzepatide effectiveness covers the full picture.

Step 4, getting a switch assessed at nume

If you are currently on semaglutide from another provider and want a prescriber to review whether tirzepatide is the right next step, the process at nume starts with a free consultation. A GPhC-registered prescriber reads your answers the same day, not at the end of a queue, not by algorithm. Transfer patients are asked to provide evidence of their current treatment and dosing history so the review is meaningful rather than perfunctory.

It is also worth knowing that a common question at this stage is whether Ozempic is tirzepatide or semaglutide, and the answer matters clinically because Ozempic is semaglutide licensed for type 2 diabetes management rather than weight loss; if your semaglutide has been prescribed off-label via Ozempic, that context matters to the prescriber. You can verify any UK online pharmacy on the GPhC register before transferring care, our registration number is 9012878. If you have questions before starting, our contact page reaches the team directly.

Suitability is a clinical call, not a box-tick. Speak to our prescribers to find out whether tirzepatide is the right step for you, and explore the full range of weight-loss treatment options to go in prepared.